27 related articles for article (PubMed ID: 38608691)
1. Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.
Janssen JC; van Dijk B; de Joode K; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; van den Eertwegh AJM; de Groot JWB; Jalving M; de Jonge MJA; Joosse A; Kapiteijn E; Kamphuis-Huismans AM; Naipal KAT; Piersma D; Rikhof B; Westgeest HM; Vreugdenhil G; Oomen-de Hoop E; Mulder EEAP; van der Veldt AAM
BMC Cancer; 2024 May; 24(1):632. PubMed ID: 38783238
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study.
Overman MJ; Gelsomino F; Aglietta M; Wong M; Limon Miron ML; Leonard G; García-Alfonso P; Hill AG; Cubillo Gracian A; Van Cutsem E; El-Rayes B; McCraith SM; He B; Lei M; Lonardi S
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38821718
[TBL] [Abstract][Full Text] [Related]
3. Usage of nivolumab and ipilimumab for recurrent or advanced malignant vaginal melanoma: a two-case series.
Konishi K; Okamoto M; Tokumitsu R; Yano M; Nasu K; Kobayashi E
Med Mol Morphol; 2024 Jun; 57(2):83-90. PubMed ID: 38289480
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma.
Yamashita S; Hamamoto S; Furukawa J; Fujita K; Takahashi M; Miyake M; Ito N; Iwamoto H; Kohjimoto Y; Hara I
Sci Rep; 2024 May; 14(1):12398. PubMed ID: 38811687
[TBL] [Abstract][Full Text] [Related]
5. Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
Yamashita S; Hamamoto S; Furukawa J; Fujita K; Takahashi M; Miyake M; Ito N; Iwamoto H; Kohjimoto Y; Hara I
Jpn J Clin Oncol; 2024 Jun; 54(6):722-729. PubMed ID: 38485656
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial.
Vos JL; Burman B; Jain S; Fitzgerald CWR; Sherman EJ; Dunn LA; Fetten JV; Michel LS; Kriplani A; Ng KK; Eng J; Tchekmedyian V; Haque S; Katabi N; Kuo F; Han CY; Nadeem Z; Yang W; Makarov V; Srivastava RM; Ostrovnaya I; Prasad M; Zuur CL; Riaz N; Pfister DG; Klebanoff CA; Chan TA; Ho AL; Morris LGT
Nat Med; 2023 Dec; 29(12):3077-3089. PubMed ID: 37620627
[TBL] [Abstract][Full Text] [Related]
7. Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use.
Li Y; Pond G; McWhirter E
Curr Oncol; 2024 Jan; 31(1):425-435. PubMed ID: 38248113
[TBL] [Abstract][Full Text] [Related]
8. Comparison of target agent treatment strategies for platinum-resistant recurrent ovarian cancer: A Bayesian network meta-analysis.
Leung JH; Leung HWC; Wang SY; Yip Fion HT; Chan ALF
Medicine (Baltimore); 2024 May; 103(21):e38183. PubMed ID: 38788019
[TBL] [Abstract][Full Text] [Related]
9. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG).
Akyildiz A; Guven DC; Koksal B; Karaoglan BB; Kivrak D; Ismayilov R; Aslan F; Sutcuoglu O; Yazici O; Kadioglu A; Alan O; Majidova N; Erciyestepe M; Ozcan E; Akdag G; Taban H; Kaya AO; Guliyev M; Yildirim N; Sakalar T; Yazilitas D; Unal C; On S; Biter S; Demirci NS; Senler FC; Kemal Y; Halil OD; Gullu I; Aksoy S
Eur Arch Otorhinolaryngol; 2024 May; ():. PubMed ID: 38795147
[TBL] [Abstract][Full Text] [Related]
10. Primary Diffuse Leptomeningeal Melanomatosis in a Child with Extracranial Metastasis: Case Report.
Shahab SW; Patil P; Fangusaro JR; Patteson B; Goldman-Yassen A; Eaton BR; Boydston W; Schniederjan M; Aguilera D
Curr Oncol; 2024 Jan; 31(1):579-587. PubMed ID: 38275834
[TBL] [Abstract][Full Text] [Related]
11. The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP).
Haj Mohammad SF; Timmer HJL; Zeverijn LJ; Geurts BS; Spiekman IAC; Verkerk K; Verbeek FAJ; Verheul HMW; Voest EE; Gelderblom H
Acta Oncol; 2024 May; 63():368-372. PubMed ID: 38779868
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
Lebbé C; Meyer N; Mortier L; Marquez-Rodas I; Robert C; Rutkowski P; Menzies AM; Eigentler T; Ascierto PA; Smylie M; Schadendorf D; Ajaz M; Svane IM; Gonzalez R; Rollin L; Lord-Bessen J; Saci A; Grigoryeva E; Pigozzo J
J Clin Oncol; 2019 Apr; 37(11):867-875. PubMed ID: 30811280
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143.
Omuro A; Vlahovic G; Lim M; Sahebjam S; Baehring J; Cloughesy T; Voloschin A; Ramkissoon SH; Ligon KL; Latek R; Zwirtes R; Strauss L; Paliwal P; Harbison CT; Reardon DA; Sampson JH
Neuro Oncol; 2018 Apr; 20(5):674-686. PubMed ID: 29106665
[TBL] [Abstract][Full Text] [Related]
14. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Paz-Ares L; Ciuleanu TE; Cobo M; Schenker M; Zurawski B; Menezes J; Richardet E; Bennouna J; Felip E; Juan-Vidal O; Alexandru A; Sakai H; Lingua A; Salman P; Souquet PJ; De Marchi P; Martin C; Pérol M; Scherpereel A; Lu S; John T; Carbone DP; Meadows-Shropshire S; Agrawal S; Oukessou A; Yan J; Reck M
Lancet Oncol; 2021 Feb; 22(2):198-211. PubMed ID: 33476593
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of nivolumab plus ipilimumab versus nivolumab alone in patients with advanced melanoma: a systematic review and meta-analysis.
Cui S; Sun X; Gao J
Expert Rev Anticancer Ther; 2024 May; 24(5):283-291. PubMed ID: 38532600
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.
Oaknin A; Moore K; Meyer T; López-Picazo González J; Devriese LA; Amin A; Lao CD; Boni V; Sharfman WH; Park JC; Tahara M; Topalian SL; Magallanes M; Molina Alavez A; Khan TA; Copigneaux C; Lee M; Garnett-Benson C; Wang X; Naumann RW
Lancet Oncol; 2024 May; 25(5):588-602. PubMed ID: 38608691
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.
Sharma P; Siefker-Radtke A; de Braud F; Basso U; Calvo E; Bono P; Morse MA; Ascierto PA; Lopez-Martin J; Brossart P; Rohrberg K; Mellado B; Fischer BS; Meadows-Shropshire S; Abdel Saci ; Callahan MK; Rosenberg J
J Clin Oncol; 2019 Jul; 37(19):1608-1616. PubMed ID: 31100038
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
